RxDoctor Payments Data

Anne Miller, MD

Glaucoma Specialist · Cheyenne, WYNPI 1255334637

Payments from drug & device makers

$15,941in general payments, 2019–2025

Across 168 payments — averaging $94.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$10K
  • Alcon$2K
  • AbbVie$2K
  • Glaukos Corporation$461
  • NEW World Medical,inc.$314
  • Mallinckrodt Hospital Products Inc.$251
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$1,33223%
  • Food & beverage$4,26174%
  • Education$982%
  • Gifts$190%
  • Entertainment$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$848,044
Medicare patients
2,044
Services billed
7,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost369$210,022
RestasisCyclosporine157$204,012
XiidraLifitegrast46$62,967
Alphagan PBrimonidine Tartrate89$41,455
RhopressaNetarsudil Mesylate76$41,115
TyrvayaVarenicline Tartrate32$35,694
RocklatanNetarsudil Mesylat/Latanoprost51$32,174
Cyclosporine38$29,447
MieboPerfluorohexyloctane/Pf15$16,756
Restasis MultidoseCyclosporine13$14,376
Brimonidine Tartrate180$14,030
Travoprost64$11,280
Dorzolamide Hcl299$7,620
SimbrinzaBrinzolamide/Brimonidine Tart27$7,545
Latanoprost433$6,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Restasis Multidose$1,704$469,865628 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$206$79,72361 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$117$73,289127 claims
Oyster Point Pharma, Inc.Tyrvaya$108$35,69432 claims
AlconSimbrinza$1,844$7,54527 claims
NovartisTravatan Z$107$3,55511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →